Notice2024-30418
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 20, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 245 (Friday, December 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 245 (Friday, December 20, 2024)]
[Notices]
[Pages 104209-104210]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-30418]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on October 4, 2024, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug
Development & Delivery
[[Page 104210]]
Consortium, Inc. (``Subcutaneous Drug Development & Delivery
Consortium, Inc.'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Janssen Research & Development, LLC, Malver, PA; Novo
Nordisk, Bagsvaerd, DENMARK; and Ypsomed AG, Burgdorf, SWITZERLAND have
been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on April 25,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on September 12, 2024 (89 FR 74288).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-30418 Filed 12-19-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on December 20, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.